Unproven stem cell-based interventions and achieving a compromise policy among the multiple stakeholders

Area of Science:

• Stem Cell Research
• Regenerative Medicine
• Clinical Trials

Background:

• Patient advocacy groups significantly influenced stem cell and regenerative medicine policy and funding.
• Following a decade of waiting for cures, many patients are now seeking experimental stem cell therapies globally.
• This has led to a phenomenon of 'stem cell tourism,' with patients bypassing domestic clinical trials.

Purpose of the Study:

• To investigate the reasons behind patients seeking experimental stem cell interventions abroad.
• To analyze the challenges and risks associated with current stem cell tourism practices.
• To propose policy solutions for re-engaging patients in US-based clinical trials.

Main Methods:

• Analysis of patient advocacy group involvement in stem cell policy.
• Examination of the current landscape of experimental stem cell-based interventions.
• Case study comparisons with HIV/AIDS and breast cancer advocacy efforts.

Main Results:

• The marketing and use of experimental stem cell interventions lack patient protection, adequate regulation, and evidence of safety and efficacy.
• Patients may incur significant financial and time costs, forgo proven treatments, and receive unverified dosages or inconsistent follow-up care.
• Current practices hinder scientific progress due to unsuitable data collection for research outcomes.

Conclusions:

• The current model of stem cell tourism is problematic and unsustainable, posing risks to patients and hindering scientific advancement.
• A re-evaluation of US clinical trial design, initiation, and conduct is necessary.
• Collaboration among scientists, clinicians, regulators, and patient advocates is crucial to develop public policy that protects patients and encourages participation in regulated clinical trials.